세계 디지털 흡입기 시장 규모는 2024-2030년의 예측 기간 동안 연평균 11.27% 성장할 것으로 예상됩니다. 시장은 천식, 만성폐쇄성폐질환(COPD), 낭포성 섬유증, 천식-COPD 중복 증후군 등 호흡기 질환의 유병률 증가 등의 요인으로 인해 상당한 시장 성장을 보이고 있습니다. 또한, 주요 제약사들의 디지털 기술 채택 급증, 대기 오염 증가, 흡연자 증가, 먼지, 연기, 공기 중 입자에 대한 노출 증가 등이 디지털 흡입기 시장을 견인할 것으로 예상됩니다. 또한, 최근 제품 출시 및 규제 당국의 승인과 같은 기술 발전은 예측 기간(2024-2030년) 동안 전체 디지털 흡입기 시장을 견인할 것으로 예상됩니다. 따라서 시장은 2024-2030년의 예측 기간 동안 상당한 CAGR로 성장할 것으로 예상됩니다.
디지털 흡입기 시장 역학
디지털 흡입기 시장을 이끄는 중요한 특징 중 하나는 다양한 호흡기 질환의 전 세계 유병률 증가입니다.
예를 들어, 세계보건기구(WHO)(2022) 데이터에 따르면, 천식은 2019년 약 2억 6,200만 명이 앓고 있으며, 같은 해 전 세계적으로 4억 5,500만 명이 사망했습니다.
또한 Global Burden of Disease Study(2019) 데이터에 따르면 COPD 유병자 수는 전 세계적으로 2억 1,230만 명으로 보고되고 있으며, 2019년 한 해 동안 330만 명이 사망했습니다. 천식과 COPD 외에도 낭포성 섬유증도 지속적으로 증가하고 있으며, March of Dimes Organization(2019)의 데이터에 따르면 2019년에 전 세계적으로 약 7만-10만 명이 낭포성 섬유증에 걸렸으며, 남성과 여성 모두 같은 비율로 발병했습니다.
또한, 대기 오염 증가는 향후 몇 년동안 디지털 흡입기에 대한 수요를 촉진할 것으로 예상됩니다. 예를 들어, Organisation for Economic Co-operation and Development(2022)에 따르면, 2022년까지 전 세계 온실가스(GHG) 배출량은 약 50% 증가할 것으로 예상되며, 이는 주로 에너지 관련 CO2 배출량이 70% 증가할 것으로 예상되기 때문입니다. 증가하기 때문입니다. 또한 GHG의 대기 중 농도는 2050년까지 CO2 환산 기준 685ppm에 도달할 수 있으며, 그 결과 금세기 말에는 세계 평균 기온이 산업혁명 이전보다 3-6도 더 높아질 것으로 예상하고 있습니다.
위 요인들과 함께 기술 개발은 지속적으로 증가하고 있으며, 이는 디지털 흡입기 시장의 성장을 가속하고 있습니다. 예를 들어, 약물 전달 시스템, 서비스 및 활성 재료 과학 솔루션의 세계 리더인 Aptar Pharma는 2022년 2월 표준 정량 분무형 흡입기(pMDI)를 스마트 커넥티드 의료기기로 전환하는 혁신적인 디지털 호흡기인 HeroTracker® Sense 건강 솔루션인 HeroTracker® Sense의 출시를 발표했습니다.
따라서 위의 요인들은 2024-2030년의 예측 기간 동안 전체 디지털 흡입기 시장을 견인할 것입니다.
그러나 높은 기기 비용과 디지털 데이터의 정확성에 대한 우려 등은 디지털 흡입기 시장의 성장에 걸림돌이 될 수 있습니다.
코로나19 팬데믹으로 인해 디지털 흡입기 시장의 제조, 공급, 수출입 및 기타 관련 활동의 혼란을 초래하는 봉쇄, 국경 폐쇄 등으로 인해 첫 몇 달 동안 디지털 흡입기 시장 성장에 다소 부정적인 영향을 미쳤습니다. 또한, 코로나19의 원인 물질인 SARS-CoV-2 바이러스의 확산에 대한 우려와 팬데믹과 관련된 불확실성으로 인해 전 세계 많은 국가들이 응급상황을 제외하고는 폐기능 검사실(PFT)을 폐쇄해야 했습니다. 그러나 중등도에서 중증의 천식이나 조절되지 않는 천식을 앓고 있는 사람들은 코로나19로 인해 입원할 가능성이 더 높았습니다. 또한, 코로나19 팬데믹은 후반기에 전 세계 사람들의 폐 건강에 대한 인식과 우려로 인해 디지털 흡입기의 성장으로 이어졌고, 이는 폐 기능 검사에 사용되는 디지털 또는 스마트 흡입기와 같은 흡입기 사용을 가속화하여 디지털 흡입기 시장 성장을 가속하고 있습니다. 촉진하고 있습니다. 또한, 디지털 흡입기의 전자상거래가 시작되면서 시장에서 수요가 증가하였습니다. 이러한 요인에 더해 높은 백신 접종률과 정부의 봉쇄 완화로 인해 디지털 흡입기에 대한 수요는 2022-2028년의 예측 기간 동안 전체 디지털 흡입기 시장을 촉진할 것으로 보입니다.
이 보고서는 세계 디지털 흡입기 시장에 대해 조사 분석했으며, 시장 규모와 예측, 촉진요인 및 과제, 기업 및 제품 프로파일 등의 정보를 전해드립니다.
DIGITAL DOSE INHALERS MARKET BY PRODUCT TYPE (DRY POWDER INHALERS AND METERED DOSE INHALERS), BY APPLICATION (CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ASTHMA, AND OTHERS), AND BY GEOGRAPHY IS EXPECTED TO ADVANCE AT A RESPECTABLE CAGR FORECAST till 2030 OWING TO THE ACCELERATING PREVALENCE OF RESPIRATORY DISORDERS SUCH AS ASTHMA, COPD, AND OTHERS, THE RISING AIR POLLUTION, AND THE GROWING NUMBER OF PRODUCT DEVELOPMENT ACTIVITIES SUCH AS PRODUCT LAUNCHES AND REGULATORY APPROVALS ACROSS THE GLOBE
The global digital dose inhalers market will grow at a CAGR of 11.27% during the forecast period from 2024 to 2030. The digital dose inhalers market is witnessing significant market growth due to the factors such as the rising prevalence of respiratory disorders such as asthma, chronic obstructive pulmonary disorder (COPD), cystic fibrosis, asthma-COPD overlap syndrome, and others. Furthermore, the surging adoption of digital technology by key pharmaceutical players, the rising air pollution, increase in the population of smokers, and increasing exposure to dust, fumes, and airborne particles will spur the market of digital dose inhalers. Additionally, the growing technological advancements such as recent product launches and regulatory approvals is expected to drive the overall market for digital dose inhalers during the forecast period (2024-2030). Therefore, the market for digital dose inhalers is estimated to grow at a substantial CAGR during the forecast period from 2024 to 2030.
DIGITAL DOSE INHALERS MARKET DYNAMICS:
One of the key aspect for driving the digital dose inhalers market is the rising prevalence of various respiratory disorders globally.
For instance, as per data by the World Health Organization (WHO) 2022, asthma affected approximately nearly 262 million people in 2019, causing 455,000 deaths in the same year, globally.
Also, according to data by the Global Burden of Disease Study (2019), there were 212.3 million prevalent cases of COPD reported globally, accounting for 3.3 million deaths in the year 2019. In addition to asthma and COPD, the numbers for cystic fibrosis are constantly on the rise. As per data by the March of Dimes Organization (2019), about 70,000 to 100,000 people had cystic fibrosis in the year 2019 globally, affecting males and females at the same rate.
Moreover, the rising air pollution is also expected to drive the demand for digital dose inhalers in the upcoming years. For instance, as per the Organization for Economic Co-operation and Development 2022, by 2050 the emission of global greenhouse gases (GHGs) could be anticipated to increase by about 50%, majorly owing to 70% growth in energy-related CO2 emissions. It also stated that the atmospheric concentration of GHGs could reach 685 parts per million (ppm) CO2- equivalents by 2050, resulting in the global average temperatures to be 3 to 6 degree Celsius above the pre-industrial levels by the end of the century.
Along with the factors mentioned above, the number of technological developments are constantly increasing, bolstering the growth of the digital dose inhalers market. For instance, in February 2022, Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, announced the launch of HeroTracker® Sense, a novel digital respiratory health solution that transforms a standard metered dose inhaler (pMDI) into a smart connected healthcare device.
Therefore, the factors stated above collectively will drive the overall digital dose inhalers market during the forecast period from 2024-2030.
However, high cost of the devices, concerns regarding the accuracy of digital data, and others may prove to be challenging factors for digital dose inhalers market growth.
The COVID- 19 pandemic had a slightly negative impact on the market growth of digital dose inhalers during the initial few months owing to the lockdown impositions, border closures, and others leading to disruption in the manufacturing, supply, import, export, and other related activities of the digital dose inhalers market. Also, owing to the fear of spread of SARS-CoV-2 virus which is the causative agent for COVID-19 and uncertainties revolving around the pandemic, many countries across the world were forced to close down pulmonary function tests (PFT) laboratories except in case of emergencies. However, people suffering from moderate-to-severe or uncontrolled asthma were more likely to get hospitalized from COVID-19. The COVID -19 pandemic also led to rise in digital dose inhalers in the later half owing to the awareness and concerns regarding lung health among the people across the world which is further accelerated the utilization of respiratory inhalers such as digital or smart inhalers for the testing of lung function, driving the market growth for digital dose inhalers. Moreover, with the commencement of e-commerce availability of digital dose inhalers, increased its demand in the market. Thus, along with the above-mentioned factors, high vaccination rates and relaxations in the government-imposed lockdown, the demand for digital dose inhalers is subjected to increase driving the overall market for digital dose inhalers during the forecast period of 2022 - 2028.
DIGITAL DOSE INHALERS MARKET SEGMENT ANALYSIS:
Digital Dose Inhalers Market by Product Type (Dry Powder Inhalers and Metered Dose Inhalers), Application (Chronic Obstructive Pulmonary Disease, Asthma, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).
In the product type segment of the digital dose inhalers market, the dry powder inhalers segment is expected to have a significant revenue share in the year 2023. This was primarily owing to the increasing prevalence of respiratory diseases, increasing technological advancements pertaining to the device, and surging launches by the key players in the market.
For instance, dry powder inhalers (DPI's) in general are easier to use than the metered dose inhalers (MDI) and cause fewer irritant effects.
Moreover, concerns related to the incidences of drug irritation caused by the presence of propellant components, such as chlorofluorocarbons (CFCs) in metered dose inhalers, have favored the adoption of the dry powder inhalers, with fewer irritant effects while delivering comparable therapeutic efficacy as metered dose inhalers. Thus, the dry powder inhalers are also known as propellant free inhalers.
Further, the DPI deposit the medicine in the lungs at a much higher rate than MDIs. This makes them more efficient and effective as they can provide a higher quantity of medicine with a single dose.
Additionally, the increasing product launches are also expected to contribute to the growth of the studied segment during the forecast period. For instance, in December 2020, Berry Global launched the RS01 single-dose dry powder inhaler with built-in sensors and digital capabilities. The RS01 tracks inhaler use and connects to a companion app that provides personalized guidance to improve adherence and inhaler technique.
Therefore, owing to the advantages associated with dry powder inhaler and increasing product launches, the category is expected to witness a considerable growth eventually contributing to the overall growth of the global digital dose inhalers market during the forecast period.
NORTH AMERICA IS EXPECTED TO DOMINATE THE OVERALL DIGITAL DOSE INHALERS MARKET:
Among all the regions, North America is expected to dominate the global digital dose inhalers market in the year 2023 and is expected to do the same during the forecast period from 2024-2030. This can be ascribed to the escalating prevalence of various respiratory disorders, increasing burden of geriatric population prone to respiratory disorder, and the presence of key market players in the region are another factors which acts as a supportive factor for the North America's digital dose inhalers market growth.
As per the data published by World Health Organization (WHO) 2022, approximately 25 million people in the United States had asthma in the year 2020 including 4.2 million children, which equals about 1 in every 13 people.
Moreover, according to the National Center for Health Statistics 2019-2020, stated that the percentage of COPD, emphysema, or chronic bronchitis for adults aged 18 and over, in the United States, increased from 4.6% in 2019 to 5.0% in 2020.
In other countries of North America such as Canada, the numbers for respiratory ailments are substantially increasing. According to statistics by the Lung Association 2020-2022, it was concluded that about 2.6 million Canadians were living with asthma in the year 2020 - 2022.
Thus, from the above sources and statistics it can be concluded that the respiratory disorders are increasing in the North America, ultimately increasing the demand of digital dose inhalers in the market.
Additionally, as per the New Mexico Department of Health Epidemiology and Response Division, 2019, in the year 2023, approximately 16.0% of adults were current smokers and nearly 32.7% of high school students were current smokers. The increasing consumption of smoking will increase the risk of developing respiratory disorders or lung cancer, ultimately increasing the demand of digital dose inhalers in order to treat and manage the respiratory disorders.
Furthermore, the increasing product launches, regulatory approvals, acquisitions, partnerships, and other activities by key players in the region will drive the market of digital dose inhalers in the upcoming years. For instance, in July 2020, Teva Pharmaceuticals, one of the prominent player in healthcare industries, announced the launch of its ProAir Digihaler in the United States. It is used in people >=4 years old to treat or prevent bronchospasm in people who have reversible obstructive airway disease or to prevent exercise-induced bronchospasm.
Henceforth, the interplay of the aforementioned factors above would provide a conducive growth environment for the North American region in the digital dose inhalers market.
DIGITAL DOSE INHALERS MARKET KEY PLAYERS:
Some of the key market players operating in the digital dose inhalers market includes Glenmark Pharmaceuticals, Novartis AG, ResMed, Koninklijke Philips N.V., Teva Pharmaceutical Industries Ltd., H&T Presspart Manufacturing Ltd., AptarGroup, Inc., Amiko Digital Health Limited., Trudell Medical UK Limited, BreatheSuite Inc., Opko Health, Inc., Cipla Inc., Sensirion AG, 3M, adherium, and others.
RECENT DEVELOPMENTAL ACTIVITIES IN DIGITAL DOSE INHALERS MARKET:
In February 2022 Astrazeneca and Honeywell partnered to develop next-generation respiratory inhalers using the propellant HFO-1234ze, which has up to 99.9% less global warming potential than propellants currently used in respiratory medicines.
In February 2019, Propeller Health, delivering one of the digital respiratory health platform, signed a partnership with Orion Corporation in order to bring the Propeller's products among European patients.
KEY TAKEAWAYS FROM THE DIGITAL DOSE INHALERS MARKET REPORT STUDY
TARGET AUDIENCE WHO CAN BE BENEFITED FROM THIS DIGITAL DOSE INHALERS MARKET REPORT STUDY
FREQUENTLY ASKED QUESTIONS FOR DIGITAL DOSE INHALERS MARKET:
The digital dose inhalers are devices that deliver a specific amount of medication to the lungs in the form of aerosolized medicine or dry powder. These inhalers have built-in sensors that detect use of inhaler and measure respiratory flow, according to the release and dose management.
The global digital dose inhalers market will grow at a CAGR of 11.27% during the forecast period from 2024 to 2030.
The digital dose inhalers market is witnessing a positive market growth owing to the factors such as increasing of prevalence of respiratory disorders such as asthma, chronic obstructive pulmonary disorder (COPD), cystic fibrosis, asthma-COPD overlap syndrome, and others. Further, the surge in the adoption of digital technology by key pharmaceutical players, rising air pollution, and increase in the population of smokers will aid in driving the market of digital dose inhalers. Also, the increasing product launches and regulatory approvals will create an exigency for the digital dose inhalers market.
Some of the key market players operating in the digital dose inhalers market includes Glenmark Pharmaceuticals, Novartis AG, ResMed, Koninklijke Philips N.V., Teva Pharmaceutical Industries Ltd., H&T Presspart Manufacturing Ltd., AptarGroup, Inc., Amiko Digital Health Limited., Trudell Medical UK Limited, BreatheSuite Inc., Opko Health, Inc., Cipla Inc., Sensirion AG, 3M, adherium, and others.
Among all the regions, North America is estimated to amass the significant revenue share in the global digital dose inhalers market. This can be ascribed to the escalating prevalence of various respiratory disorders, increasing burden of geriatric population prone to respiratory disorder, and the presence of key market players in the region are another factors which acts as a supportive factor for the North America's digital dose inhalers market growth.